With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...

Automation and quality control (QC) are critical in manufacturing safe and effective cell and gene therapy products. However, current QC methods, reliant on molecular staining, pose difficulty in ...

Chimeric antigen receptor (CAR) -T-cell therapies have yielded remarkable results in the treatment of hematological malignancies. Several autologous CAR T-cell products have received marketing ...

CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The ...

Automation, decentralized manufacturing, and supportive regulations are helping to surmount technical difficulties in cell and gene therapy manufacturing.

Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...

A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

Pascal Touchon serves as global strategy advisor to RoslinCT and board director, bringing over four decades of international experience in the biopharmaceutical industry, combining operational ...

Cellares, in collaboration with Mitsui Fudosan, a Japanese real estate developer, established Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...